

This document is an English-translated version of an attachment of a notification for Revision of PRECAUTIONS issued by the Ministry of Health, Labour and Welfare.

This English version is intended to be a reference material to provide convenience for users.

In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Revision of PRECAUTIONS

Eplerenone

May 20, 2025

Therapeutic category

Antihypertensives

Non-proprietary name

Eplerenone

Safety measure

PRECAUTIONS should be revised.

Revised language is underlined.

Current			Revision		
<p>2. CONTRAINDICATIONS (This drug is contraindicated to the following patients.)</p> <p><Common to all indications></p> <p>Patients receiving the following drugs: Itraconazole, preparations containing ritonavir, and ensitrelvir fumaric acid</p>			<p>2. CONTRAINDICATIONS (This drug is contraindicated to the following patients.)</p> <p><Common to all indications></p> <p>Patients receiving the following drugs: Itraconazole, <u>voriconazole</u>, <u>posaconazole</u>, preparations containing ritonavir, and ensitrelvir fumaric acid</p>		
<p>10. INTERACTIONS</p> <p>10.1 Contraindications for Co-administration (Do not co-administer with the following.)</p> <p><Common to all indications></p>			<p>10. INTERACTIONS</p> <p>10.1 Contraindications for Co-administration (Do not co-administer with the following.)</p> <p><Common to all indications></p>		
Drugs	Signs, symptoms, and treatment	Mechanism/risk factors	Drugs	Signs, symptoms, and treatment	Mechanism/risk factors
Itraconazole Preparations containing ritonavir Ensitrelvir fumaric acid	The plasma concentration of eplerenone may increase, and an increase in serum potassium levels may be induced.	The metabolism of eplerenone is suppressed by a strong CYP3A4-inhibitor.	Itraconazole <u>Voriconazole</u> <u>Posaconazole</u> Preparations containing ritonavir Ensitrelvir fumaric acid	The plasma concentration of eplerenone may increase, and an increase in serum potassium levels may be induced.	The metabolism of eplerenone is suppressed by a strong CYP3A4-inhibitor.